Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 15/20 | 0.62 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814582 | 0.88 | IL2 (0.49) | IL2ABL1 | |
| SCHEMBL4764238 | 0.87 | IL2 (0.66) | IL2RAF1BRAFCREBBP | |
| SCHEMBL2816312 | 0.86 | IL2 (0.50) | IL2 | |
| SCHEMBL2817751 | 0.85 | IL2 (0.69) | IL2ABL1 | |
| SCHEMBL2814805 | 0.84 | IL2 (0.53) | IL2RAF1BRAF | |
| SCHEMBL2813178 | 0.83 | IL2 (0.64) | IL2ABL1 | |
| SCHEMBL5029396 | 0.83 | IL2 (0.48) | IL2 | |
| SCHEMBL8239294 | 0.82 | IL2 (0.67) | IL2ABL1 | |
| SCHEMBL2816403 | 0.82 | IL2 (0.65) | IL2ABL1 | |
| SCHEMBL5550955 | 0.82 | IL2 (0.64) | IL2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-03 | — | — | US | claimed |
| US-8710083-B2 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-29 | — | — | US | claimed |
| EP-1984338-B1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-01-16 | — | — | EP | claimed |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-09-30 | — | — | US | claimed |
| EP-1984338-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | claimed |
| WO-2007089904-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-09 | — | — | WO | claimed |
| US-10798940-B2 | Penflufen polymer particles | LANXESS DEUTSCHLAND GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-10604685-B2 | Aqueous polymer dispersions for composite film lamination | BASF SE (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20180242588-A1 | BIOCIDAL MIXTURES | LANXESS DEUTSCHLAND GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-20180235222-A1 | PENFLUFEN POLYMER PARTICLES | LANXESS DEUTSCHLAND GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| EP-2676976-B2 | Emulsion Polymers With Improved Wet Scrub Resistance Having One Or More Silicon Containing Compounds | CELANESE SALES GERMANY GMBH (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20180118985-A1 | AQUEOUS POLYMER DISPERSIONS FOR COMPOSITE FILM LAMINATION | BASF SE (DE) | 2018-05-03 | — | — | US | disclosed |
| WO-2007089904-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060257673-A1 | Laminates, their production and use | CELANESE EMULSIONS GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20050124759-A1 | Aqueous coating compositions method for the production thereof and their use for producing in particular thixotropic coating compositions | CELANESE EMULSIONS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| US-6451899-B1 | Aqueous formulations comprising at least two different polymers as aqueous dispersions | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| US-5646325-A | Process for the preparation of 3-acryloyloxypropylalkoxysilanes | HUELS AKTIENGESELLSCHAFT (DE) | 1997-07-08 | — | — | US | disclosed |
| US-4579809-A | Positive image formation | CIBA-GEIGY CORPORATION (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0053010-B1 | ACIDIC ADHESIVE COMPOSITIONS AND IMAGE RECORDING PRODUCTS CONTAINING SAME | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | CCR1, CXCR3, NLRP1 | IL2 77/4885ABL1 2986/4885RAF1 2343/4885 |
| US-20140187586-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCR3, NLRP1 | IL2 77/4885ABL1 2986/4885RAF1 2343/4885 |
| US-20180242588-A1 | BIOCIDAL MIXTURES | PUF60, BTF3, AOC3 | IL2 2369/4885ABL1 2404/4885RAF1 4668/4885 |
| US-10798940-B2 | Penflufen polymer particles | FAP, PUF60, MATR3 | IL2 1586/4885ABL1 2944/4885RAF1 4206/4885 |
| US-20100249195-A1 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCR3, NLRP1 | IL2 77/4885ABL1 2986/4885RAF1 2343/4885 |
| US-20180235222-A1 | PENFLUFEN POLYMER PARTICLES | FAP, PUF60, MATR3 | IL2 1586/4885ABL1 2944/4885RAF1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.